Platelet Biogenesis is an allogeneic cell therapy company that focuses on platelet biology.
Platelet BioGenesis has raised $75.5M in total funding. The most recent round was Series B. The last funding was announced in November 2021.
Platelet BioGenesis's investors include Qiming Venture Partners, Vivo Capital, Oxford Finance LLC, U.S. Department of War, Massachusetts Life Sciences Center.
Platelet BioGenesis is headquartered in Watertown, United States.
Platelet Biogenesis is an allogeneic cell therapy company that focuses on platelet biology.
Platelet BioGenesis is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Platelet BioGenesis — Funding & Investors." VCBacked, November 4, 2021, https://www.vcbacked.co/company/platelet-biogenesis. Accessed July 20, 2026.
VCBacked. (2021). Platelet BioGenesis — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/platelet-biogenesis
{{cite web |title=Platelet BioGenesis — Funding & Investors |url=https://www.vcbacked.co/company/platelet-biogenesis |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated